Thalidomide
"Thalidomide" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
Descriptor ID |
D013792
|
MeSH Number(s) |
D02.241.223.805.810.800 D03.383.621.808.800 D03.438.513.750.750
|
Concept/Terms |
Thalomid- Thalomid
- Celgene Brand of Thalidomide
|
Below are MeSH descriptors whose meaning is more general than "Thalidomide".
Below are MeSH descriptors whose meaning is more specific than "Thalidomide".
This graph shows the total number of publications written about "Thalidomide" by people in this website by year, and whether "Thalidomide" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
Year | Major Topic | Minor Topic | Total |
---|
1999 | 1 | 0 | 1 | 2000 | 1 | 0 | 1 | 2002 | 1 | 1 | 2 | 2003 | 2 | 0 | 2 | 2005 | 1 | 0 | 1 | 2007 | 1 | 0 | 1 | 2008 | 2 | 0 | 2 | 2009 | 1 | 1 | 2 | 2010 | 1 | 1 | 2 | 2011 | 2 | 1 | 3 | 2012 | 2 | 4 | 6 | 2014 | 3 | 1 | 4 | 2015 | 2 | 2 | 4 | 2016 | 1 | 3 | 4 | 2017 | 5 | 2 | 7 | 2018 | 0 | 1 | 1 | 2020 | 0 | 1 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Thalidomide" by people in Profiles.
-
Menter A, Gelfand JM, Connor C, Armstrong AW, Cordoro KM, Davis DMR, Elewski BE, Gordon KB, Gottlieb AB, Kaplan DH, Kavanaugh A, Kiselica M, Kivelevitch D, Korman NJ, Kroshinsky D, Lebwohl M, Leonardi CL, Lichten J, Lim HW, Mehta NN, Paller AS, Parra SL, Pathy AL, Prater EF, Rahimi RS, Rupani RN, Siegel M, Stoff B, Strober BE, Tapper EB, Wong EB, Wu JJ, Hariharan V, Elmets CA. Joint American Academy of Dermatology-National Psoriasis Foundation guidelines of care for the management of psoriasis with systemic nonbiologic therapies. J Am Acad Dermatol. 2020 Jun; 82(6):1445-1486.
-
Imamura T, Kinugawa K, Uriel N. Therapeutic Strategy for Gastrointestinal Bleeding in Patients With Left Ventricular Assist Device. Circ J. 2018 11 24; 82(12):2931-2938.
-
Ross LF. 50 Years Ago in The Journal of Pediatrics: Editorial Comment: Therapeutic Orphans. J Pediatr. 2018 01; 192:59.
-
Ruddy KJ, Navari RM, Loprinzi CL. Thalidomide: Rebirth of a Gestational Antiemetic? J Clin Oncol. 2017 11 01; 35(31):3523-3524.
-
Holstein SA, Jung SH, Richardson PG, Hofmeister CC, Hurd DD, Hassoun H, Giralt S, Stadtmauer EA, Weisdorf DJ, Vij R, Moreb JS, Callander NS, van Besien K, Gentile TG, Isola L, Maziarz RT, Bashey A, Landau H, Martin T, Qazilbash MH, Rodriguez C, McClune B, Schlossman RL, Smith SE, Hars V, Owzar K, Jiang C, Boyd M, Schultz C, Wilson M, Hari P, Pasquini MC, Horowitz MM, Shea TC, Devine SM, Linker C, Anderson KC, McCarthy PL. Updated analysis of CALGB (Alliance) 100104 assessing lenalidomide versus placebo maintenance after single autologous stem-cell transplantation for multiple myeloma: a randomised, double-blind, phase 3 trial. Lancet Haematol. 2017 Sep; 4(9):e431-e442.
-
Sekeres MA, Othus M, List AF, Odenike O, Stone RM, Gore SD, Litzow MR, Buckstein R, Fang M, Roulston D, Bloomfield CD, Moseley A, Nazha A, Zhang Y, Velasco MR, Gaur R, Atallah E, Attar EC, Cook EK, Cull AH, Rauh MJ, Appelbaum FR, Erba HP. Randomized Phase II Study of Azacitidine Alone or in Combination With Lenalidomide or With Vorinostat in Higher-Risk Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: North American Intergroup Study SWOG S1117. J Clin Oncol. 2017 Aug 20; 35(24):2745-2753.
-
Badros A, Hyjek E, Ma N, Lesokhin A, Dogan A, Rapoport AP, Kocoglu M, Lederer E, Philip S, Milliron T, Dell C, Goloubeva O, Singh Z. Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma. Blood. 2017 09 07; 130(10):1189-1197.
-
Dimopoulos MA, Stewart AK, Masszi T, Špicka I, Oriol A, Hájek R, Rosiñol L, Siegel D, Mihaylov GG, Goranova-Marinova V, Rajnics P, Suvorov A, Niesvizky R, Jakubowiak A, San-Miguel J, Ludwig H, Ro S, Aggarwal S, Moreau P, Palumbo A. Carfilzomib-lenalidomide-dexamethasone vs lenalidomide-dexamethasone in relapsed multiple myeloma by previous treatment. Blood Cancer J. 2017 04 21; 7(4):e554.
-
Smith SM, Pitcher BN, Jung SH, Bartlett NL, Wagner-Johnston N, Park SI, Richards KL, Cashen AF, Jaslowski A, Smith SE, Cheson BD, Hsi E, Leonard JP. Safety and tolerability of idelalisib, lenalidomide, and rituximab in relapsed and refractory lymphoma: the Alliance for Clinical Trials in Oncology A051201 and A051202 phase 1 trials. Lancet Haematol. 2017 Apr; 4(4):e176-e182.
-
Mark TM, Guarneri D, Forsberg P, Rossi A, Pearse R, Perry A, Pekle K, Tegnestam L, Greenberg J, Shore T, Gergis U, Mayer S, Van Besien K, Ely S, Jayabalan D, Sherbenou D, Coleman M, Niesvizky R. A Phase I Trial of High-Dose Lenalidomide and Melphalan as Conditioning for Autologous Stem Cell Transplantation in Relapsed or Refractory Multiple Myeloma. Biol Blood Marrow Transplant. 2017 Jun; 23(6):930-937.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|